Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Amortization - Intangibles: 2023-2025

Historic Amortization - Intangibles for Zevra Therapeutics (ZVRA) over the last 2 years, with Sep 2025 value amounting to $315,000.

  • Zevra Therapeutics' Amortization - Intangibles fell 79.61% to $315,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 4.25%. This contributed to the annual value of $6.2 million for FY2024, which is 707.64% up from last year.
  • According to the latest figures from Q3 2025, Zevra Therapeutics' Amortization - Intangibles is $315,000, which was down 80.51% from $1.6 million recorded in Q2 2025.
  • Zevra Therapeutics' 5-year Amortization - Intangibles high stood at $1.6 million for Q4 2024, and its period low was $315,000 during Q3 2025.
  • Its 3-year average for Amortization - Intangibles is $1.3 million, with a median of $1.5 million in 2024.
  • In the last 5 years, Zevra Therapeutics' Amortization - Intangibles surged by 109.33% in 2024 and then tumbled by 79.61% in 2025.
  • Over the past 3 years, Zevra Therapeutics' Amortization - Intangibles (Quarterly) stood at $772,000 in 2023, then surged by 109.33% to $1.6 million in 2024, then slumped by 79.61% to $315,000 in 2025.
  • Its last three reported values are $315,000 in Q3 2025, $1.6 million for Q2 2025, and $1.6 million during Q1 2025.